A citation-based method for searching scientific literature

Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 76



Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2019
Times Cited: 29




List of shared articles



Times cited

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
11

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
6

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
13

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
2

Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney. Diabetes Obes Metab 2021
1


A review of sotagliflozin for use in type 1 diabetes.
Wesley Nuffer, Briana Williams, Jennifer M Trujillo. Ther Adv Endocrinol Metab 2019
5



Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Bertrand Cariou, Satish Garg, Michael J Davies, Kiernan Seth, Sangeeta Sawhney. Diab Vasc Dis Res 2021
0

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
11


Critical Reappraisal of the Time-in-Range: Alternative or Useful Addition to Glycated Hemoglobin?
Lutz Heinemann, Guido Freckmann, Dirk Müller-Wieland, Monika Kellerer. J Diabetes Sci Technol 2020
2

A comparison of sotagliflozin therapy for diabetes mellitus between week 24 with week 52 : A protocol for mixed treatment comparisons meta-analysis.
Nie Zhang, Zhi-Qun Gu, Yun-Long Ding, Liu Yang, Mao-Bing Chen, Qi-Han Zheng. Medicine (Baltimore) 2019
0

SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu. Ther Adv Endocrinol Metab 2020
3

Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis.
Mao-Bing Chen, Rui-Jun Xu, Qi-Han Zheng, Xu-Wen Zheng, Hua Wang. Medicine (Baltimore) 2020
2

An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Georgios Chatzopoulos, Konstantinos Tziomalos. Expert Opin Pharmacother 2020
1

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
9